What is Glycotest?
Glycotest Diagnostics is at the forefront of developing innovative, non-invasive blood tests designed to identify liver cancers and fibrosis-cirrhosis. Their core technology leverages proprietary biomarkers and advanced assays to analyze standard blood samples, aiming to provide early detection for individuals at high risk due to chronic liver conditions. The company's algorithm-driven approach targets a significant global health challenge, as liver cancer remains a leading cause of cancer-related mortality. Glycotest's strategic focus on early intervention through accessible diagnostic tools positions it as a key player in the preventative healthcare and medical diagnostics sector.
How much funding has Glycotest raised?
Glycotest has raised a total of $10M across 1 funding round:
Series A
$10M
Series A (2018): $10M with participation from Fosun Pharmaceutical Co. and Shanghai Fosun Pharmaceutical Co. , Ltd.
Key Investors in Glycotest
Fosun Pharmaceutical Co.
Fosun Pharmaceutical Co. is a significant entity in the healthcare sector, likely focusing on pharmaceutical development and medical device innovation. Their investment in Glycotest suggests a strategic interest in advancing diagnostic technologies for critical diseases.
Shanghai Fosun Pharmaceutical Co. , Ltd.
As a prominent pharmaceutical conglomerate, Shanghai Fosun Pharmaceutical Co., Ltd. typically invests in companies that align with their broad healthcare portfolio, potentially seeking to enhance their offerings in diagnostic solutions and early disease detection.
What's next for Glycotest?
With the recent major strategic investment, Glycotest is poised to accelerate its research and development initiatives, potentially expanding its diagnostic panel and refining its proprietary algorithms. This capital infusion is expected to support clinical validation studies, regulatory submissions, and the scaling of manufacturing capabilities. The company's trajectory suggests a move towards broader market adoption, aiming to integrate its non-invasive testing solutions into routine patient care pathways for individuals susceptible to liver diseases. Further strategic partnerships or enterprise-level funding may be anticipated as Glycotest seeks to establish a dominant presence in the liver disease diagnostics market.
See full Glycotest company page
